HLN Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

Informazioni su Haleon plc American Depositary Shares (Each representing two Ordinary Shares) Panoramica della società da Wikipedia

Haleon plc is a British multinational consumer healthcare company with headquarters in Weybridge, England. It is one of the largest consumer healthcare businesses in the world, with brands including Sensodyne toothpaste, Panadol and Advil painkillers, and Centrum vitamins. The company was projected to be a global leader in over the counter medicines with a 7.3 per cent market share in 2022.

Leggi di più

Haleon plc is a British multinational consumer healthcare company with headquarters in Weybridge, England. It is one of the largest consumer healthcare businesses in the world, with brands including Sensodyne toothpaste, Panadol and Advil painkillers, and Centrum vitamins. The company was projected to be a global leader in over the counter medicines with a 7.3 per cent market share in 2022.

Haleon was established on 18 July 2022 as a corporate spin-off from GSK. Haleon is listed on the London Stock Exchange and is a component of the FTSE 100, with a secondary listing on the New York Stock Exchange.

History

GSK and Pfizer merged their consumer healthcare businesses in 2019. GSK owned just over two thirds of the joint venture, and Pfizer owned the remainder. Annual sales were around £10 billion across 120 markets in 2020. GSK then announced plans to spin off Haleon in 2022 to give the "tired drugmaker extra focus and firepower by gearing up and hiving off the consumer division," according to Reuters. Unilever offered £50 billion for the business in 2022, which GSK rejected. Nestlé examined the possibility of a bid in conjunction with Reckitt. In October 2023, GSK reduced its ownership in Haleon to 7.4%, and in January 2024 it further reduced its ownership to 4.2%.

In August 2023, Haleon sold its Lamisil antifungal brand to Karo Healthcare AB for £235 million, and in February 2024, Haleon sold its ChapStick lip care brand to Yellow Wood Partners for £401 million.

In March 2024, Pfizer reduced its share in Haleon from 32% to 24% per cent by selling 630 million shares in a public offering.

Further sales followed: in April 2024, Haleon announced that it would close its Sensodyne toothpaste factory in Maidenhead, moving that manufacturing to Slovakia, and it outsourced mouthwash manufacturing to an unrelated company and, in September 2024, the company completed the sale of its non-US nicotine replacement therapy business to Dr. Reddy's Laboratories in a deal worth £458 million.

In March 2025, Pfizer sold its entire stake in Haleon for £2.5 billion ($3.24 billion), exiting the consumer healthcare business it helped create by its 2019 joint venture with GSK.

Operations

Oral health accounted for 28.5 percent of revenue in 2021.

Sir Dave Lewis is chairman, with Brian McNamara as chief executive.

Brands

Current

Brands include:

=== Divested ===

Fonte: Wikipedia (Inglese), CC BY-SA 4.0 · Vedi su Wikipedia ↗

Wikidata ↗

HLN Snapshot del titolo Prezzo, capitalizzazione di mercato, P/E, EPS, ROE, debito/capitale proprio, intervallo 52 settimane

Performance decennale Andamento di ricavi, utile netto, margini e EPS

Valutazione Rapporti P/E, P/S, P/B, EV/EBITDA — il titolo è costoso o economico?

Redditività Margini lordi, operativi e netti; ROE, ROA, ROIC

Salute finanziaria Debito, liquidità, solvibilità — solidità del bilancio

Crescita Crescita di ricavi, EPS e utile netto: YoY, CAGR 3Y, CAGR 5Y

Metriche per Azione EPS, valore contabile per azione, flusso di cassa per azione, dividendo per azione

Efficienza del Capitale Rotazione delle attività, rotazione delle scorte, rotazione dei crediti

Dividendi Rendimento, payout ratio, storico dividendi, CAGR 5Y

HLN Consenso degli analisti Opinioni degli analisti, sia rialziste che ribassiste, target price a 12 mesi, potenziale di rialzo

Cronologia utili EPS effettivo vs stima, surprise %, tasso di superamento, data prossimi utili

Ultime notizie Notizie recenti che menzionano questa società

• Haleon Recalls Certain Gas-X Extra Strength Softgels Nasdaq · 2 mesi, 2 settimane fa

Proprietari istituzionali (13F) 687 filer · $3.8B totale · Aggiornato al 30 Giugno 2026

Istituzioni che segnalano il possesso di questo titolo nel loro Modulo SEC 13F trimestrale. Solo posizioni lunghe; un singolo depositante può apparire due volte per diverse gambe di opzioni. Grandi posizioni put/call contrapposte riflettono tipicamente market-making o inventario coperto, non convinzione direzionale.

Attivisti e proprietari del 5%+ 2 partecipazioni

Investitori che hanno depositato SEC Schedule 13D — proprietà effettiva superiore al 5% con l'intento di influenzare l'emittente (partecipazioni attiviste, campagne per il consiglio di amministrazione, M&A). Ogni riga mostra lo stato più recente noto della posizione di quel depositante.

Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.

Proprietà ETF Posseduti da 36 ETF

Il peso riflette solo le partecipazioni azionarie dirette (N-PORT); fondi a leva o basati su derivati possono detenere ulteriore esposizione swap non mostrata.